FdaApplication
NDA 209401
Identifiers
- fda_app_no: NDA209401
Properties
| Property | Value |
|---|---|
| applicant_name | JAZZ PHARMACEUTICALS THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2017-08-03 |
Revenue by product
VYXEOS
| Period | Revenue |
|---|---|
| Q2 2026 | $31.4M* |
| Q1 2026 | $26.6M* |
| Q4 2025 | $34.7M* |
| Q3 2025 | $37.6M* |
| Q2 2025 | $44.9M* |
| Q1 2025 | $29.5M* |
| Q4 2024 | $53.2M* |
| Q3 2024 | $34.3M* |
| Q2 2024 | $43.0M* |
| Q1 2024 | $32.0M* |
| Q4 2023 | $46.9M* |
| Q3 2023 | $29.8M* |
| Q2 2023 | $34.1M* |
| Q1 2023 | $36.7M* |
| Q4 2022 | $30.3M* |
| Q3 2022 | $30.1M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VYXEOS | CYTARABINE; DAUNORUBICIN | 100MG;44MG | POWDER;INTRAVENOUS |
1 product